Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
An update from Acrivon Therapeutics, Inc. ( (ACRV) ) is now available.
On January 8, 2026, Acrivon Therapeutics hosted a corporate webcast and conference call to present updated clinical data for its lead oncology programs ACR-368 and ACR-2316, alongside broader AP3 pipeline developments. The company highlighted Phase 2b data from its ACR-368-201 (GOG-3082) trial in endometrial cancer, including an overall response rate of 39% for ACR-368 monotherapy in OncoSignature-positive patients and 26% for the ACR-368 plus ultra-low-dose gemcitabine combination, as well as particularly strong responses in biomarker-selected and serous endometrial cancer subgroups; these results, derived from non–QC’ed data as of December 4, 2025, support ACR-368’s registrational-intent pathway and reinforce Acrivon’s biomarker-driven strategy in a tumor type with significant unmet need, potentially strengthening its competitive positioning in precision oncology.
The most recent analyst rating on (ACRV) stock is a Hold with a $3.00 price target. To see the full list of analyst forecasts on Acrivon Therapeutics, Inc. stock, see the ACRV Stock Forecast page.
Spark’s Take on ACRV Stock
According to Spark, TipRanks’ AI Analyst, ACRV is a Neutral.
The score is primarily constrained by weak financial performance (no revenue, large and persistent losses, and significant ongoing cash burn), despite a low-debt balance sheet. Technicals are supportive with price above key moving averages and positive MACD. Recent positive clinical updates provide an additional tailwind, while valuation metrics are less informative due to negative earnings and no dividend.
To see Spark’s full report on ACRV stock, click here.
More about Acrivon Therapeutics, Inc.
Acrivon Therapeutics, Inc. is a next-generation precision medicine company focused on oncology, using its AI-driven Acrivon Predictive Precision Proteomics (AP3) platform to match dysregulated disease pathways with targeted therapies. The company’s pipeline centers on small-molecule inhibitors such as ACR-368, a selective CHK1/CHK2 inhibitor in registrational-intent Phase 2b development, and ACR-2316, a dual WEE1/PKMYT1 inhibitor in early-stage clinical trials, with additional programs including a CDK11 candidate (ACR-6840) and other AP3-driven oncology and autoimmune/inflammatory projects.
Average Trading Volume: 790,599
Technical Sentiment Signal: Buy
Current Market Cap: $94.98M
Find detailed analytics on ACRV stock on TipRanks’ Stock Analysis page.